Matthias Schroff

USPTO Granted Patents = 12 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 144(Granted Patents)

Company Filing History:

Mologen Forschungs Entwicklungs Und Vertriebs Gmbh

patents

2 out of 923

Gilead Sciences, Inc.

patents

Years Active: 2002-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11583581 - Methods of treating a retroviral infection (2023-02-21),

2. 11578331 - Combination comprising immunostimulatory oligonucleotides (2023-02-14),

3. 10604760 - Combination comprising immunostimulatory oligonucleotides (2020-03-31),

4. 10487333 - Combination comprising immunostimulatory oligonucleotides (2019-11-26),

5. 10280424 - Covalently closed non-coding immunomodulatory DNA construct (2019-05-07),

6. 10006032 - Predictive biomarker for cancer therapy (2018-06-26),

7. 9499815 - Multimer for immunostimulation (2016-11-22),

8. 9012620 - DNA constructs for specific inhibition of gene expression by RNA interference (2015-04-21),

9. 8017591 - Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals (2011-09-13),

10. 7915035 - Vaccine against oncovirus infections such as infections by feline leukosis virus of the cat (2011-03-29),

11. 6849725 - Covalently closed nucleic acid molecules for immunostimulation (2005-02-01),

12. 6451563 - Method for making linear, covalently closed DNA constructs (2002-09-17),

Title: Matthias Schroff: Innovator in Viral Infection Treatment

Introduction

Matthias Schroff is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of viral infections. With a total of 12 patents to his name, Schroff's work has the potential to impact the lives of many patients suffering from retroviral infections.

Latest Patents

Among his latest patents, Schroff has developed methods for treating retroviral infections. This invention involves a non-coding sequence of deoxyribonucleic acids that includes at least one sequence motif NNCGNN. This sequence is utilized in conjunction with antiretroviral therapy and/or histone de-acetylase inhibitors to enhance treatment efficacy. Another notable patent focuses on a combination of immunostimulatory oligonucleotides for treating various diseases. This combination includes a T-cell regulator and a non-coding immunomodulating DNA, showcasing Schroff's innovative approach to immunotherapy.

Career Highlights

Throughout his career, Matthias Schroff has worked with several notable companies, including Mologen AG and Mologen Forschungs Entwicklungs Und Vertriebs GmbH. His experience in these organizations has allowed him to refine his research and development skills, contributing to his success as an inventor.

Collaborations

Schroff has collaborated with esteemed colleagues such as Manuel Schmidt and Burghardt Wittig. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of medical research.

Conclusion

Matthias Schroff's contributions to the field of viral infection treatment through his innovative patents highlight his dedication to improving healthcare. His work continues to pave the way for new therapeutic approaches that could benefit countless individuals.

This text is generated by artificial intelligence and may not be accurate.